HDAC6-selective inhibitors enhance anticancer effects of paclitaxel in ovarian cancer cells

JUNG YOO, YU HYUN JEON, DONG HOON LEE, GO WOON KIM, SANG WU LEE, SO YEON KIM, JONGSUN PARK, SO HEE KWON

Research output: Contribution to journalArticlepeer-review

Abstract

Histone deacetylase 6 (HDAC6)-selective inhibitors are potent anticancer agents that are gaining increasing attention and undergoing various developments. These have been approved or are under clinical trials for use with other anticancer agents, such as pomalidomide, anti-programmed death-ligand 1 antibody and paclitaxel, for various types of cancer, including solid tumors. In the present study, a second generation HDAC6-selective inhibitor, ACY-241 (citarinostat), and a novel inhibitor, A452, exhibited synergistic anticancer effects with paclitaxel in AT-rich interaction domain 1A-mutated ovarian cancer in vitro. Co-treatment of paclitaxel and the two HDAC6 inhibitors synergistically decreased cell growth and viability of TOV-21G. Furthermore, the protein expression levels of pro-apoptotic markers, such as poly(ADP-ribose) polymerase, cleaved caspase-3, Bak and Bax, were increased, whereas the expression levels of anti-apoptotic markers, such as Bcl-xL and Bcl-2, were decreased synergistically. Treatment with all drug combinations increased the portion of apoptotic cells in fluorescence-activated cell sorting analysis. These results demonstrated synergy between paclitaxel and HDAC6-selective inhibitors, providing further impetus for clinical trials of combination therapy using HDAC6-selective inhibitors, not only in ovarian cancer but also in other tumors.

Original languageEnglish
Article numbere12462
JournalOncology Letters
Volume21
Issue number3
DOIs
Publication statusPublished - 2021 Mar

Bibliographical note

Funding Information:
The present study was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (grant nos. 2018R1A6A1A03023718 and 2019R1I1A1A01058601).

Publisher Copyright:
© 2021 Spandidos Publications. All rights reserved.

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'HDAC6-selective inhibitors enhance anticancer effects of paclitaxel in ovarian cancer cells'. Together they form a unique fingerprint.

Cite this